Revolution Medicines (RVMD) Corporate presentation summary

Vision and strategy

• Focused on creating a global franchise of targeted medicines for RAS-addicted cancers, leveraging a proprietary tri-complex platform for continuous innovation, broad clinical development, and commercial excellence.

• Pipeline targets major RAS variants across pancreatic, lung, and colorectal cancers, aiming to change global standards of care.

• Discovery, development, and delivery pillars drive a virtuous cycle of innovation and patient impact.

Clinical pipeline and key data

• Daraxonrasib demonstrated a 60% reduction in risk of death and median OS >1 year in previously treated metastatic pancreatic cancer, with a favorable safety profile.

• Zoldonrasib and daraxonrasib combinations showed high response rates and disease control in first-line and previously treated PDAC, with manageable safety.

• In NSCLC, daraxonrasib and zoldonrasib monotherapies and combinations with standard of care showed promising efficacy and tolerability, including in patients with prior immunotherapy and chemotherapy.

• Elironrasib, a G12C-selective inhibitor, showed activity in NSCLC, including in patients previously treated with G12C (OFF) inhibitors, and in combination with daraxonrasib.

• Early clinical and preclinical data support expansion into colorectal cancer and the development of next-generation RAS (ON) inhibitors.

Regulatory and commercial progress

• NDA for daraxonrasib accepted by FDA; EMA review underway; U.S. commercial launch readiness achieved.

• Expanded access program provided daraxonrasib to over 2,000 patients nationwide.

• Multiple Phase 3 registrational trials ongoing or initiated across PDAC, NSCLC, and CRC.

• Launch-ready U.S. commercial infrastructure and accelerating global launch capabilities.